FibroGen/Astellas’ E
FibroGen/Astellas’ EVRENZO (roxadustat) Making In-Roads in European Market as In-Class Challenger, Akebia/Medice’s VAFSEO (vadadustat), Prepares for Launch in Early 2024.
08 déc. 2023 09h10 HE | Spherix Global Insights
Exton, Pennsylvania, Dec. 08, 2023 (GLOBE NEWSWIRE) -- EVRENZO made history as the initial hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) to receive EU approval in August 2021,...
Akebia’s Vafseo (vad
Akebia’s Vafseo (vadadustat) Poised to Make Waves for GSK’s Jesduvroq and FibroGen/Astellas’ Evrenzo
20 juil. 2023 15h07 HE | Spherix Global Insights
Exton, Pennsylvania, July 20, 2023 (GLOBE NEWSWIRE) -- Nephrologists have long awaited the approval of HIF-PH inhibitors for the treatment of anemia in their chronic kidney disease (CKD) patients....
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management
07 nov. 2022 16h00 HE | FibroGen, Inc.
Strengthens balance sheet with strategic non-dilutive capital to support strategic prioritiesSupported by global launches of EVRENZO™ in the territories partnered with Astellas Pharma Inc.FibroGen...